title: Similarity of symptoms between transient epileptic amnesia and Lewy body disease.
abstract: Epilepsy with the main symptom of amnesia is known as transient epileptic amnesia (TEA). Dementia with Lewy bodies (DLB) is the second most common form of neurodegenerative dementia. The concept that Lewy body disease includes Parkinson's disease with dementia and dementia with Lewy bodies was proposed in the 2005 revision of the Clinical Diagnostic Criteria. Here, we describe a woman with cognitive impairment, olfactory dysfunction, and reduced123I-meta-iodobenzylguanidine uptake on myocardial scintigraphy. The patient and her family and friends were unaware of parkinsonism, visual hallucinations, or epilepsy for a long period. After syncope occurred twice within a short interval, electroencephalography revealed sharp waves from the bilateral frontal to parietal lobes, indicating a diagnosis of TEA. The present case prompted us to compare the symptoms of TEA with the clinical diagnostic criteria for dementia with Lewy bodies, revealing their similarities. We also discuss whether Lewy body disease may cause TEA rather than having an incidental association with it.
authors.affiliation: Department of Psychogeriatrics, Kamiiida Daiichi General Hospital, Nagoya, Japan.|Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Ukai
authors.affiliation: Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Hiroshige
authors.initials: H
authors.lastname: Fujishiro
authors.affiliation: Shinjuku Shinkei Clinic, Tokyo, Japan.
authors.forename: Masako
authors.initials: M
authors.lastname: Watanabe
authors.affiliation: Clinic Ian Center Minami, Yokohama, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Kosaka
authors.affiliation: Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Norio
authors.initials: N
authors.lastname: Ozaki
mesh_terms: D019797:3-Iodobenzylguanidine / Q000378:metabolism; D000368:Aged; D000647:Amnesia / Q000150:complications / Q000175:diagnosis*; D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use; D003072:Cognition Disorders / Q000209:etiology; D004569:Electroencephalography; D005260:Female; D006212:Hallucinations / Q000150:complications; D006801:Humans; D000077287:Levetiracetam; D020961:Lewy Body Disease / Q000175:diagnosis* / Q000188:drug therapy; D055414:Myocardial Perfusion Imaging; D020734:Parkinsonian Disorders / Q000150:complications; D010889:Piracetam / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D012640:Seizures / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D000927:Anticonvulsants; D019797:3-Iodobenzylguanidine; D000077287:Levetiracetam; D010889:Piracetam
keywords: 
  Lewy body disease; complex partial seizures; dementia with Lewy bodies; levetiracetam; temporal lobe epilepsy; transient epileptic amnesia